Skip to main content
SpringerLink
Log in

Hypericum extract LI 160 and fluoxetine in mild to moderate depression

A randomized, placebo–controlled multi–center study in outpatients

  • ORIGINAL PAPER
  • Published:
European Archives of Psychiatry and Clinical Neuroscience Aims and scope Submit manuscript

Abstract

Efficacy and tolerability of Hypericum LI 160 was compared to fluoxetine and placebo in mild to moderate Major Depression (DSM–IV) in a 4–week randomized, double–blind trial. One hundred and sixtythree outpatients from 15 general practitioner centers received either 900 mg Hypericum LI 160, 20 mg fluoxetine, or placebo daily. Amelioration was measured by the Hamilton and the Montgomery–Åsberg Depression scales. Response and remission rates and global ratings by investigators and patients were measured. Adverse event reports, laboratory screening, vital signs, physical exams and ECG were collected. No significant differences could be observed regarding efficacy measures except for remission rate (Hypericum 24%; fluoxetine 28%; placebo 7 %). Hypericum was significantly better tolerated than fluoxetine. Hypericum LI 160 or fluoxetine were not more effective in short–term treatment in mild to moderate depression than placebo.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Similar content being viewed by others

References

  1. American Psychiatric Association (1994) Diagnostic and Statistical Manual of Mental Disorders (DSM-IV). American Psychiatric Press: Washington DC

    Google Scholar 

  2. Baker CB, Johnsrud MT,Crismon ML, Rosenheck RA,Woods SW (2003) Quantitative analysis of sponsorship bias in economic studies of antidepressants. Br J Psychiatry 183:498–506

    Article  PubMed  Google Scholar 

  3. Brenner R, Azbel V, Madhusoodanan S, Pawlowska M (2000) Comparison of an extract of hypericum (LI 160) treatment of depression: a double-blind, randomized pilot study. Clin Ther 22:411–419

    Article  CAS  PubMed  Google Scholar 

  4. Brenner R, Bjerkenstedt L, Edman GV (2002) Hypericum perforatum extract (St. John’s wort) for depression. Psychiatr Ann 32:21–26

    Google Scholar 

  5. Chilvers C, Dewey M, Fielding K, Gretton V, Miller PR, Palmer BW, Weller D, Churchill R, Williams I, Bedi N, Duggan C, Lee A, Harrison G (2001) Antidepressant drugs and generic counselling for treatment of major depression in primary care: randomised trial with patient preference arms. Br Med J 322:772–775

    CAS  Google Scholar 

  6. Deltito J,Beyer D (1998) The scientific, quasi-scientific and popular literature on the use of St. John’s Wort in the treatment of depression. J Affective Disord 51:345–351

    Article  CAS  Google Scholar 

  7. Doogan DP, Langdon CJ (1994) A double-blind, placebo-controlled comparison of sertraline and dothiepin in the treatment of major depression in general practice. Int Clin Psychopharmacol 9:95–100

    CAS  PubMed  Google Scholar 

  8. Ernst E, Rand JI, Barnes J, Stevinson C (1998) Adverse effects profile of the herbal antidepressant St. Johns wort (Hypericum perforatum L.). Eur J Clin Pharmacol 54:589–594

    Article  CAS  PubMed  Google Scholar 

  9. The European Agency for the Evaluation of Medicinal Products (1998) Concept paper on the revision of the committee for proprietary medicinal products (CPMP) note for guidance on medicinal products for the treatment of depression (CPMP/EWP/ 518/97 concept paper). London: EMEA

  10. Fabre LF, Putman HPr (1987) A fixed-dose clinical trial of fluoxetine in outpatients with major depression. J Clin Psychiatry 48:406–408

    CAS  PubMed  Google Scholar 

  11. Gupta RK, Möller HJ (2003) St. John’s Wort.An option for the primary care treatment of depressive patients? Eur Arch Psychiatry Clin Neurosci 253:140–148

    CAS  PubMed  Google Scholar 

  12. Guy W (1976) ECDEU Assessment Manual for Psychopharmacology (76–338) Rockville, Md: US Department of Health, Education, and Welfare publication (ADM)

  13. Hamilton M (1967) Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 6:278–296

    CAS  PubMed  Google Scholar 

  14. Harrer G, Schmidt U, Kuhn U, Biller A (1999) Äquivalenzvergleich Johanniskrautextrakt LoHyp-57 versus Fluoxetin. Arzneim Forsch/Drug Res 49:3–10

    Google Scholar 

  15. Hoffmann J, Kühl ED (1979) Therapie von depressiven Zuständen mit Hypericin. Zeitschrift für Allgemeinmedizin 55:776–782

    CAS  Google Scholar 

  16. Hypericum Depression Trial Study Group (2002) Effect of Hypericum perforatum (St. John’s Wort) in major depressive disorder: a randomized controlled trial. JAMA 287:1807–1814

    Article  PubMed  Google Scholar 

  17. Khan A, Leventhal RM, Khan SR, Brown WA (2002) Severity of depression and response to antidepressants and placebo: an analysis of the Food and Drug Administration database. J Clin Psychopharmacol 22:40–45

    PubMed  Google Scholar 

  18. Kim HL, Streltzer J, Goebert D (1999) St. John’s wort for depression. A meta-analysis of well-defined clinical trials. J Nerv Ment Dis 187:532–539

    CAS  PubMed  Google Scholar 

  19. Kirsch I, Sapirstein G (1998) Listening to Prozac but hearing placebo: a meta-analysis of antidepressant medication. Retrieved from the World Wide Web: http://journals.apa.org/ prevention/volume1/pre0010002a.html

  20. Linde K, Ramirez G, Mulrow CD, Pauls A, Weidenhammer W, Melchart D (1996) St John’s wort for depression – an overview and meta-analysis of randomised clinical trials. Br Med J 313:253–258

    CAS  Google Scholar 

  21. Linde K, ter Riet G, Hondras M,Vickers A, Saller R,Melchert D (2001) Systematic reviews of complementary therapies – an annotated bibliography. Part 2: Herbal medicine. BMC Complementary Alternative Medicine

    Google Scholar 

  22. Lingjaerde O, Ahlfors UG, Bech P, Dencker SJ, Elgen K (1987) The UKU side effect rating scale. A new comprehensive rating scale for psychotropic drugs and a cross-sectional study of side effects in neuroleptic-treated patients. Acta Psychiatr Scand 334:1–100

    Google Scholar 

  23. Montgomery SA (1999) The failure of placebo-controlled studies. Eur Neuropsychopharmacol 9:271–276

    Google Scholar 

  24. Montgomery SA, Åsberg M (1979) A new depression scale designed to be sensitive to change. Br J Psychiatry 133:382–389

    Google Scholar 

  25. Müller MJ, Himmerich H, Kienzle B, Szegedi A (2003) Differentiating moderate and severe depression using the Montgomery- Asberg depression rating scale (MADRS). J Affective Disord 77:255–260

    Article  Google Scholar 

  26. Parker G, Anderson IM, Haddad P (2003) Clinical trials of antidepressant medications are producing meaningless results. Br J Psychiatry 183:102–104

    PubMed  Google Scholar 

  27. Schrader E (2000) Equivalence of St John’s wort extract (Ze 117) and fluoxetine: a randomized, controlled study in mild-moderate depression. Int Clin Psychopharmacol 15:61–68

    CAS  PubMed  Google Scholar 

  28. Shelton RC, Keller MB, Gelenberg A, Dunner DL, Hirschfeld R, Thase ME, Russell J, Lydiard RB, Crits-Cristoph P, Gallop R, Todd L, Hellerstein D, Goodnick P, Keitner G, Stahl SM, Halbreich U (2001) Effectiveness of St John’s wort in major depression: a randomized controlled trial. JAMA 285:1978–1986

    Article  CAS  PubMed  Google Scholar 

  29. Stevinson C,Ernst E (1999) Safety of Hypericum in patients with depression. CNS Drugs 11:125–132

    CAS  Google Scholar 

  30. Stokes PE, Holtz A (1997) Fluoxetine tenth anniversary update: the progress continues. Clin Ther 5:1135–1250

    Article  Google Scholar 

  31. Walsh BT, Seidman SN, Sysko R, Gould M (2002) Placebo response in studies of major depression: variable, substantial, and growing. 287:1840–1847

  32. World Health Organisation (1999) Adverse Reactions Terminology (WHO-ART). Uppsala: World Health Organisation

  33. WMA (2000) Declaration of Helsinki. World Medical Association, www.wma.net/e/policty/17-c_e.html. Retrieved from the World Wide Web

  34. Volz HP (1997) Controlled clinical trials of Hypericum extracts in depressed patients – an overview. Pharmacopsychiatry 30:72–76

    Google Scholar 

  35. Volz HP, Laux P (2000) Potential treatment for subthreshold and mild depression: a comparison of St. John’s wort extracts and fluoxetine. Compr Psychiatry 41:133–137

    Google Scholar 

  36. Vorbach EU, Arnoldt KH, Wolpert E (2000) St. Johns wort.A potential therapy for elderly depressed patients? Drugs Aging 16:189–197

    CAS  PubMed  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Dept. of Clinical Neuroscience, Psychiatry Section Karolinska Hospital, 17176, Stockholm, Sweden

    L. Bjerkenstedt MD

  2. Dept. of Psychiatry Research and Development Unit , Danderyd’s Hospital, Danderyd, Sweden

    G. V. Edman

  3. Cooperative Clinical Drug Research and Development AG, Neuenhagen, Germany

    R. G. Alken

  4. Lichtwer Pharma GmbH, Berlin, Germany

    M. Mannel

Authors
  1. L. Bjerkenstedt MD
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. G. V. Edman
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. R. G. Alken
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. M. Mannel
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to L. Bjerkenstedt MD.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bjerkenstedt, L., Edman, G.V., Alken, R.G. et al. Hypericum extract LI 160 and fluoxetine in mild to moderate depression. Eur Arch Psychiatry Clin Neurosci 255, 40–47 (2005). https://doi.org/10.1007/s00406-004-0532-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00406-004-0532-z

Key words

Search

Navigation